Scholarly article on topic 'Hepatitis E virus seroprevalence among schistosomiasis patients in Northeastern Brazil'

Hepatitis E virus seroprevalence among schistosomiasis patients in Northeastern Brazil Academic research paper on "Health sciences"

CC BY-NC-ND
0
0
Share paper
OECD Field of science
Keywords
{Brazil / Epidemiology / "Hepatitis E virus" / Schistosomiasis / Seroprevalence}

Abstract of research paper on Health sciences, author of scientific article — Ana Maria Passos-Castilho, Anne de Sena, Ana Lucia Coutinho Domingues, Edmundo Pessoa Lopes-Neto, Tibério Batista Medeiros, et al.

Abstract Background Hepatitis E virus (HEV) can cause chronic infection with rapid progression to liver cirrhosis in immunocompromised patients. HEV seroprevalence in patients with Schistosoma mansoni in Brazil is unknown. We evaluated the prevalence of past or present HEV infection in schistosomiasis patients in Recife, Pernambuco, Brazil. A total of 80 patients with Schistosoma mansoni were consecutively enrolled in a cross-sectional study. Serum samples were tested for the presence of anti-HEV IgG antibodies by enzyme immunoassay (Wantai anti-HEV IgG, Beijing, China) and for the presence of HEV RNA using real time reverse transcriptase-polymerase chain reaction with primers targeting the HEV ORF2 and ORF3. Clinical and laboratory tests as well as abdominal ultrasound were performed at the same day of blood collection. Results Anti-HEV IgG was positive in 18.8% (15/80) of patients with SM. None of the samples tested positive for anti-HEV IgM or HEV-RNA. Patients with anti-HEV IgG positive presented higher levels of alanine aminotranferase (p =0.048) and gama-glutamil transferase (p =0.022) when compared to patients without anti-HEV IgG antibodies. Conclusion This study demonstrates that the seroprevalence of HEV is high in patients with Schistosoma mansoni in Northeastern of Brazil. Past HEV infection is associated with higher frequency of liver enzymes abnormalities. HEV infection and its role on the severity of liver disease should be further investigated among patients with Schistosoma mansoni.

Academic research paper on topic "Hepatitis E virus seroprevalence among schistosomiasis patients in Northeastern Brazil"

BJID 5671-5

ARTICLE IN PRESS

braz j infect dis 2016;xxx(xx):xxx-xxx

The Brazilian Journal of

INFECTIOUS DISEASES

www.elsevier.com/locate/bjid

1 Original article

2 Hepatitis E virus seroprevalence among

3 schistosomiasis patients in Northeastern Brazil

4 qi Ana Maria Passos-Castilhoa, Anne de Senaa,b, Ana Lucia C. Dominguesd,

5 Edmundo P. Lopesd, Tiberio Batista Medeirosd, Celso F.H. Granatoa'b,

6 Maria Lucia Ferrazc'*

7 Q2 a Division of Infectious Diseases, Federal University of Sao Paulo, Brazil

8 b Fleury SA Group, Brazil

9 Q3 c Division of Gastroenterology, Federal University of Sao Paulo, Sao Paulo, SP, Brazil

10 d Division of Gastroenterology, Federal University ofPernambuco, PE, Brazil

article info

abstract

14 Article history:

i5Q4 Received 9 November 2015

16 Accepted 2 March 2016

17 Available online xxx

20 21 22

Keywords: Brazil

Epidemiology Hepatitis E virus Schistosomiasis Seroprevalence

Bacfeground:Hepatitis E virus (HEV) can cause chronic infection with rapid progression to liver cirrhosis in immunocompromised patients. HEV seroprevalence in patients with Schistosoma mansoni (SM) in Brazil is unknown. We evaluated the prevalence of past or present HEV infection in schistosomiasis patients in Recife, Pernambuco, Brazil. A total of 80 patients with SM were consecutively enrolled in a cross-sectional study. Serum samples were tested for the presence of anti-HEV IgG antibodies by enzyme immunoassay (Wantai anti-HEV IgG, Beijing, China) and for the presence of HEV RNA using real time reverse transcriptase-polymerase chain reaction with primers targeting the HEV ORF2 and ORF3. Clinical and laboratory tests as well as abdominal ultrasound were performed at the same day of blood collection.

Results:Anti-HEV IgG was positive in 18.8% (15/80) of patients with SM. None of the samples tested positive for anti-HEV IgM or HEV-RNA. Patients with anti-HEV IgG positive presented higher levels of ALT (p = 0.048) and GGT (p = 0.022) when compared to patients without anti-HEV IgG antibodies.

Conclusion:This study demonstrates that the seroprevalence of HEV is high in patients with SM in Northeastern of Brazil. Past HEV infection is associated with higher frequency of liver enzymes abnormalities. HEV infection and its role on the severity of liver disease should be further investigated among patients with SM.

© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author at: 1726 Rua Loefgren, Sao Paulo, SP 04039032, Brazil. E-mail address marialucia.ferraz@uol.com.br (M.L. Ferraz). http://dx.doi.Org/10.1016/j.bjid.2016.03.001

1413-8670/© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

JID 5671-5

ARTICLE IN PRESS

braz j infect dis. 2016;xxx(xx):xxx-xxx

Introduction

Hepatitis E virus (HEV) presents as large epidemics and sporadic cases in endemic areas, including genotype 1 in Asia and Africa, genotype 2 in Mexico and Africa, and genotype 4 in Asia. Sporadic cases of genotype 3 occur in Europe, Japan and the Americas. Genotypes 1 and 2 are restricted to primates and are transmitted predominantly by the fecal-oral route. Genotypes 3 and 4 infect numerous mammalian species and can be transmitted through the ingestion of raw or undercooked meat from infected animals.1

HEV infection usually presents as an acute self-limiting hepatitis, but in immunocompromised patients it can cause chronic infection with rapid progression to liver cirrhosis.2 Brazil has been classified as moderately endemic for HEV, with seroprevalence ranging from 1% to 4% in the general population and 15% in renal transplant recipients.3,4

Schistosoma mansoni (SM) is endemic in up to eight countries and islands in Latin America and the Caribbean, including Brazil. Up to 6 million people are infected, most of whom live in Northeastern Brazil and Venezuela, and 25 million are at risk for the infection.5 Schistosomiasis mansoni may progress to the most advanced form of disease, which is commonly observed in endemic areas. When this hepatosplenic form occurs in association with other hepatic disease, such as viral hepatitis, hepatic fibrosis can progress into cirrhosis within a few years.6

The seroprevalence of HEV in patients with SM in Brazil is unknown. The aim of this study was to evaluate the prevalence of past or present HEV infection in a sample of schistosomiasis patients in Recife, an endemic region of Northeastern, Brazil, and to associate the positivity to HEV infection to clinical and laboratory abnormalities.

to be included patients ought to have periportal fibrosis (PPF) on ultrasound evaluation of the liver.

Male and female patients aged 14 years or older with SM diagnosis were included. Those with the following criteria were excluded: presence of markers for hepatitis B or C (anti-HBc and anti-HCV); alcohol intake >210 g/week; and ultrasound evidence of other liver disease, as expressed by the presence of steatosis or fine fibrosis diffused throughout the parenchyma.

During the study period 122 patients were evaluated; however, 42 patients (32.7%) were excluded due to co-infection with HBV and/or HCV, alcohol abuse, or other liver diseases as shown on liver ultrasound. Therefore, 80 patients were included in this study.

Ultrasound exams were performed by a single operator (ALCD) using the Siemens Acuson X 150® device with a 3.5 MHz convex transducer for the evaluation of periportal fibrosis based on the Niamey classification, which has six pre-established patterns of fibrosis (PPF) intensity, ranging from Pattern A (normal) to Pattern F (very advanced fibrosis).9

According to the pattern of PPF by ultrasound, patients were divided into three groups: (1) mild group PPF: A + B; (2) moderate PPF: C + D; and (3) advanced PPF E + F.

Sample and data collection

Serum samples from these patients were collected for laboratory analysis. These included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), gamma-glutamyl transpeptidase (GGT), total protein and albumin, total bilirubin, hemoglobin, leukocyte, and platelet count.

Normal levels of liver enzymes were ALT <31 UI/L; AST < 31UI/L, AP < 105 UI/L; and GGT < 41UI/L.

80 81 82

100 101 102

Patients and methods

56 Study area

57 Recife is the seventh largest metropolitan area in Brazil with

58 approximately 3.9 million inhabitants, the second largest

59 metropolitan area of the Northern/Northeastern Regions, and

60 the capital and largest city of the state of Pernambuco.7 In

61 addition, the hospital where the study was carried out is

62 a reference center for patients with the most severe forms

63 of schistosomiasis mansoni and receives patients from both

64 Recife metropolitan region as well as from the endemic zone

65 of Pernambuco State.8

66 Study design

67 A cross-sectional study was carried out involving patients with

68 SM who consecutively underwent an ultrasound exam over a

69 nine-month period at the Division of Gastroenterology, of the

70 Federal University of Pernambuco, Brazil. The diagnosis of SM

71 was based on their clinical history of contact with contami-

72 nated water, positive parasitological stool examination for SM

73 and/or reports of prior treatment for this parasite. In addition,

Anti-HEV antibodies detection 106

The presence of anti-HEV IgG antibodies was investigated i07

through enzyme immunoassay using the WANTAI HEV-IgG 108

ELISA kit (Beijing Wantai Biological Pharmacy Enterprise, 109

Beijing, China), strictly according to the manufacturer's rec- 110

ommendations. Specimens with positive results were tested 111

for anti-HEV IgM antibodies using a specific kit from the same 112

manufacturer. 113

RNA extraction and quantitative RT-PCR 114

HEV RNA was extracted from fecal samples using QIAamp viral 115

RNA mini kit (QIAGEN, Hilden, Germany), strictly according to 116

the manufacturer's instructions. 117

Quantitative RT-PCR was performed according to a mod- 118

ified 1-step triplex real time protocol previously described10 119

with a set of primers and probe targeting a highly conserved 120

70 nt long sequence within overlapping parts of ORF2 and 121

ORF3,11 and another set specific for a 113 nt sequence of 122

ORF2.12 A third set of primers and probe targeting the human 123

RNAseP gene was used as endogenous internal amplification 124

control to certify specimen quality and RNA extraction.13 125

A plasmid clone from a Brazilian human HEV strain previ- 126

ously characterized (GenBank accession number KF1528840)14 127

BJID 5671-5

ARTICLE IN PRESS

braz j infect dis. 2016;xxx(xx):xxx-xxx

Table 1 - Demographic, clinical and laboratory characteristics of schistosomiasis patients according to anti-HEV IgG status, Northeastern Brazil.

Characteristic Anti-HEV IgG positive Anti-HEV IgG negative p-Value Total

Sex Male Female 7(25.0) 8 (15.4) 21 (75.0) 44 (84.6) NS 28 (35.0) 52 (65.0)

Age Fibrosis pattern Mild Moderate Advanced 49.2 ± 14.9 1 (50.0) 10 (19.2) 4 (15.4) 50.3 ±13.4 1 (50.0) 42 (80.8) 22 (84.6) NS NS 50.2 ±13.7 2 (2.5) 52 (65.0) 26 (32.5)

Laboratory data AST ALT AP GGT Total bilirubin Albumin Total protein Hemoglobin Leucocytes Platelets 36.1 ±19.4 40.5 ± 28.3 126.7 ±47.4 104.7 ±65.9 1.3 ± 1.1 4.2 ±0.5 7.6 ±0.7 12.7 ±1.7 4395 ± 1467 136,933 ±90,066 30.3 ±16.4 30.6 ±18.7 116.9 ±50.6 71.0 ±60.7 1.3 ±0.9 4.3 ±0.7 7.3 ±1.0 13.3 ±1.8 4979 ±2175 132,261 ±84,434 NS 0.048* NS 0.022* NS NS NS NS NS NS 31.5 ± 17.0 32.6 ±21.0 118.9 ±49.9 77.4 ±62.6 1.3 ±0.9 4.3 ±0.6 7.3 ±1.0 13.2 ±1.8 4858 ± 2065 132,263 ±85,093

Total 15 (18.8) 65 (81.2) 80 (100)

Results are presented as number and percentage for categorical variables and as mean value and standard deviation for continuous variables. Conventional symbols used: -p >0.050. Note: Student's t-test was used for means comparison of normally distributed variables while Mann-Whitney U test was used for medians comparison of non-normally distributed variables. Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; GGT, gama-glutamyl transpeptidase. * Significant at p < 0.050 in Student's t-test.

was constructed with TOPO® TA cloning® kit (Invitrogen, Carlsbad, CA, USA) and the primers described. Plasmid DNA was purified using QIAprep spin miniprep kit (QIAgen, Hilden, Germany), linearized and quantified with the Nan-odrop ND-1000 instrument (Wilmington, DE, USA) following transcription to RNA with T7 RNA polymerase (Promega, Madison, WI, USA). Standard curves were generated using 100 to 1010 copies of plasmid RNA. HEV viral loads were determined based on the standard curves. While qualitative real time RT-PCR showed a limit of detection of 5 copies of RNA per reaction, the linearity of quantitation was set as 50 copies of RNA per reaction (lowest reproducible viral load). All screening reactions were run in duplicates, with positive results confirmed in a separate confirmatory reaction.

Statistical analysis

All data were stored and analyzed using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics consisted of the characterization of the studied population (demographic, clinical and laboratory characteristics) and anti-HEV IgG sero-prevalence through the respective rates or mean/median and standard deviation (SD) for continuous variables. The univari-ate analysis consisted of Pearson's Chi-square test to compare categorical values. For continuous variables, Student's t-test was used to compare means of normally distributed variables, while non-normally distributed variables were subjected to Mann-Whitney U test for comparison of medians. Statistical significance level was p<0.05. All reported values are two-tailed.

The study protocol was approved by the Institutional Ethics 157 Committee (162/09 and 86730/14) and all participants signed 158 an informed consent form. 159

160 161 162

The present data demonstrate that severe cases of SM con- 175 tinue to take place among outpatients in Northeastern, Brazil. 176 Close to one-third (32.5%) of the patients exhibited advanced 177

Ethical aspects

Results

Study subjects were 14-78 years old, median age 51 years old (mean ±SD: 50.2 ±13.7); 52 (65%) patients were female. Schistosomiasis was clinically classified as mild (2/80; 2.5%), moderate (52/80; 65%), or severe (26/80; 32.5%), based on staging of periportal fibrosis, according to Niamey classification.15

Anti-HEV IgG was positive in 15 of the 80 schistosomiasis patients (18.8%). None of the samples tested positive for anti-HEV IgM or HEV-RNA. Demographic, clinical and laboratory data are shown in Table 1.

Patients with anti-HEV IgG antibodies showed significant increase in ALT, and GGT levels, when compared to patients with no evidence of HEV infection. Other laboratory parameters as well as the grade of liver fibrosis determined by ultrasound analysis showed no differences between the two groups.

Discussion

JID 5671-5

ARTICLE IN PRESS

braz j infect dis. 2016;xxx(xx):xxx-xxx

patterns (E and F) of periportal fibrosis. These patients with more advanced fibrosis and with low complete blood count presented with the hepatosplenic form of disease.16 Additionally, they showed higher levels of portal pressure and consequently a greater risk of digestive bleeding, requiring follow up in reference centers.9,17

In studies from 1997 to 2006, anti-HEV IgG prevalence varied from 2.0% to 4.3% in blood donors from Southeast and Northeast Brazil, and from 0% to 2.4% in individuals from rural and urban areas and in those living in low socioeconomic communities.18 A study on 699 patients of low-socioeconomic status living in Rio de Janeiro in 2002 reported a 2.4% seroprevalence.19

HEV seroprevalence rates appear to have increased in recent years.20 Indeed, in more recent studies, the prevalence of HEV infection varied from 5.1% in recyclable waste pickers from Central Brazil,21 10% in blood donors from the Southern part of the country,22 and 12.9% in rural Amazonia.23

In the present study we found a prevalence of 18.8% of anti-HEV IgG among a sample of schistosomiasis patients. Such prevalence is higher than that observed in immuno-competent populations in the country.18-23 There is only one study from Brazil that included, among other groups, patients with SM. In this study, 10% (3/30) of patients with SM were HEV IgG positive, also pointing to a high prevalence of HEV in this specific group of patients.24 Other studies with Egyptian patients have also demonstrated a higher prevalence of HEV infection in schistosomiasis patients.25-27 The higher prevalence of HEV infection in the schistosomiasis patients evaluated in the present study could be explained by the low socioeconomic conditions of these patients, which could have favored acquisition of both infections. Moreover, schistosomiasis may play a role in virus infection by altering host immune response, favoring the acquisition of infection. In fact, many studies demonstrate that the chronic phase of schistosomiasis infection is characterized by a state of immune hyporesponsiveness.28 Immunocompro-mised patients are known to be more susceptible to hepatitis E infection and even to chronic hepatitis E with rapidly progressive cirrhosis, a condition that was not detected in the present study. Fulminant hepatitis and higher mortality are also seen in individuals with underlying chronic liver disease.1,2 In developed countries, smaller studies have shown a poor prognosis for patients with underlying chronic liver disease, but it is not clear how frequently it occurs, as such patients are not routinely tested for evidence of HEV infection.1

In the present study, schistosomiasis patients with anti-HEV IgG antibodies showed significantly higher levels of ALT and GGT, when compared to patients with no evidence of past HEV infection. Although schistosomiasis per se can be associated with abnormal liver tests, mainly GGT,29,30 in the present study HEV infection seems to have contributed to the finding of more elevated levels of the liver enzymes. Accordingly, some studies have reported that anti-HEV IgG positive patients have higher levels of liver enzymes, when compared to non-infected patients.31,32 In the study by Hassing et al.,32 HIV-infected patients with anti-HEV IgG antibodies showed higher levels of ALT, when compared to anti-HEV IgG negative patients, and this elevation was not due to acute or chronic infection, since all patients were anti-HEV IgM and HEV-RNA

negative, like in the present study. The finding of elevated ALT and GGT in patients with past HEV-infection, with or without underlying liver disease, merits further investigation in order to understand the mechanisms involved in these abnormalities.

In conclusion, this study demonstrates a higher seropreva-lence of past HEV-infection in patients with SM from Recife, Northeastern Brazil. Also, schistosomiasis patients with evidence of past HEV-infection have higher levels of ALT and GGT, suggesting an interaction between these two liver diseases. Further studies are necessary to evaluate the epidemiology of HEV infection in SM patients and its impact on the severity of the disease.

Funding

This work was partially supported by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [grant numbers 2012/229253, 2013/03701-0].

Conflicts of interest Q5

The authors declare no conflicts of interest. references

1. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus 257 infection. Clin Microbiol Rev. 2014;27:116-38. 258

2. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated 259 with chronic hepatitis in patients with hepatitis E virus 260 infection who have received solid organ transplants. 261 Gastroenterology. 2011;140:1481-9. 262

3. Echevarría JM, González JE, Lewis-Ximenez LL, et al. Hepatitis 263 E virus infection in Latin America: a review. J Med Virol. 264 2013;85:1037-45. 265

4. Hering T, Passos AM, Perez RM, et al. Past and current 266 hepatitis E virus infection in renal transplant patients. J Med 267 Virol. 2014;86:948-53. 268

5. World Health Organization. Elimination of schistosomiasis 269 from low-transmission areas. Report of a WHO Informal 270 Consultation, Salvador; 2008. Available at: 271 http://www.who.int/schistosomiasis/resources/en/ [accessed 272 20.01.15]. 273

6. Van-Lume DS, Albuquerque Mde F, Souza AI, et al. 274 Association between Schistosomiasis mansoni and hepatitis 275 C: systematic review. Rev Saude Publica. 2013;47:414-24. 276

7. Brazilian Institute of Geography and Statistics. Population 277 estimates; 2014. Available at: 278 http://saladeimprensa.ibge.gov.br/noticias [accessed 279 20.01.15]. 280

8. Silva PC, Leal TV, Domingues AL. Treatment and education 281 reduce the severity of schistosomiasis periportal fibrosis. Rev 282 Soc Bras Med Trop. 2013;46:472-7. 283

9. Richter J, Monteiro Eda S, Braz RM, et al. Sonographic 284 organometry in Brazilian and Sudanese patients with 285 hepatosplenic schistosomiasis mansoni and its relation to 286 the risk of bleeding from oesophageal varices. Acta Trop. 287 1992;51:281-90. 288

10. Vasickova P, Kralik P, Slana I, Pavlik I. Optimisation of a triplex 289

real time RT-PCR for detection of hepatitis E virus RNA and 290

validation on biological samples. J Virol Methods. 291

2012;180:38-42. 292

ARTICLE IN PRESS

BJID 5671-5

braz j infect dis. 2016;xxx(xx):xxx-xxx

293 11. Jothikumar N, Cromeans TL, Robertson BH, Meng XJ, Hill VR.

294 A broadly reactive one-step real-time RT-PCR assay for rapid

295 and sensitive detection of hepatitis E virus. J Virol Methods.

296 2006;131:65-71.

297 12. Gyarmati P, Mohammed N, Norder H, Blomberg J, Belak S,

298 Widen F. Universal detection of hepatitis E virus by two

299 real-time PCR assays: TaqMan and Primer-Probe Energy

300 Transfer. J Virol Methods. 2007;146:226-35.

301 13. Luo W, Yang H, Rathbun K, Pau CP, Ou CY. Detection of human

302 immunodeficiency virus type 1 DNA in dried blood spots by a

303 duplex real-time PCR assay. J Clin Microbiol. 2005;43:1851-7.

304 14. Passos-Castilho AM, Porta G, Miura IK, et al. Chronic hepatitis

305 E virus infection in a pediatric female liver transplant

306 recipient. J Clin Microbiol. 2014;52:4425-7.

307 15. El Scheich T, Holtfreter MC, Ekamp H, et al. The WHO

308 ultrasonography protocol for assessing hepatic morbidity due

309 to Schistosoma mansoni. Acceptance and evolution over 12

310 years. Parasitol Res. 2014;113:3915-25.

311 16. Domingues ALC, Lima ARF, Dias HS, Leäo GC, Coutinho A. An

312 ultrasonographic study of liver fibrosis in patients infected

313 with Schistosoma mansoni in north-east Brazil. Trans R Soc

314 Trop Med Hyg. 1993;87:555-8.

315 17. Dias HS, Domingues ALC, Cordeiro FTM, Juca NT, Lopes EP.

316 Associating portal congestive gastropathy and hepatic

317 fibrosis in hepatosplenic mansoni schistosomiasis. Acta Trop.

318 2013;126:240-3.

319 18. Carrilho FJ, Mendes Clemente C, Silva LC. Epidemiology of

320 hepatitis A and E virus infection in Brazil. Gastroenterol

321 Hepatol. 2005;28:118-25.

322 19. Santos DC, Souto FJ, Lopes dos Santos DR, Vitral CL, Gaspar

323 AM. Seroepidemiological markers of enterically transmitted

324 viral hepatitis A and E in individuals living in a community

325 located in the North Area of Rio de Janeiro, RJ, Brazil. Mem

326 Inst Oswaldo Cruz. 2002;97:637-40.

327 20. Passos-Castilho AM, de Sena A, Reinaldo MR, Granato CF.

328 Hepatitis E virus infection in Brazil: results of

329 laboratory-based surveillance from 1998 to 2013. Rev Soc Bras

330 Med Trop. 2015;48:468-70.

331 21. Martins RM, Freitas NR, Koslowski A, et al. Seroprevalence of

332 hepatitis E antibodies in a sample of recyclable waste pickers in Brazil. J Med Virol. 2014;59:188-91.

22. Passos-Castilho AM, de Sena A, Geraldo A, Spada C, Granato 333 CF. High prevalence of hepatitis E virus antibodies among Q6 334 blood donors in Southern Brazil. J Med Virol. 2015 335 (in press). 336

23. Vitral CL, da Silva-Nunes M, Pinto MA, et al. Hepatitis A and E 337 seroprevalence and associated risk factors: a 338 community-based cross-sectional survey in rural Amazonia. 339 BMC Infect Dis. 2014 [Published online in August 23, 340 2014]. 341

24. Parana R, Cotrim HP, Cortey-Boennec ML, Trepo C, Lyra L. 342 Prevalence of hepatitis E virus IgG antibodies in patients from 343 referral unit of liver diseases in Salvador, Bahia, Brazil. Am J 344 Trop Med Hyg. 1997;57:60-1. 345

25. Abdel Rahman MM, Massoud AM, Kamel MA, Sabry AH, 346 Ahmed GN. Risk of hepatitis "E" virus infection among some 347 schistosomiasis patients in Egypt. J Egypt Soc Parasitol. 348 1995;25:115-23. 349

26. Divizia M, Gabrieli R, Stefanoni ML, et al. HAV and HEV 350 infection in hospitalised hepatitis patients in Alexandria, 351 Egypt. Eur J Epidemiol. 1999;15:603-9. 352

27. El-Esnawy NA, Al-Herrawy AZ. Seroprevalence of certain 353 hepatitis viruses among Egyptian workers infected with 354 schistosomiasis. J Egypt Public Health Assoc. 2000;75: 355 357-66. 356

28. Jenkins SJ, Hewitson JP, Jenkins GR, Mountford AP. Modulation 357 of the host's immune response by schistosome larvae. 358 Parasite Immunol. 2005;27:385-93. 359

29. Balbaa M, El-Kersh M, Mansour H, et al. Activity of some 360 hepatic enzymes in schistosomiasis and concomitant 361 alteration of arylsulfatase B. J Biochem Mol Biol. 362 2004;37:223-8. 363

30. Al Mofarreh MA, Al Akwaa AY, Al Mofleh IA. Gammaglutamyl 364 transpeptidase activity in patients with schistosomiasis. 365 Saudi J Gastroenterol. 2003;9:15-9. 366

31. Lagler H, Poeppl W, Winkler H, et al. Hepatitis E virus 367 seroprevalence in Austrian adults: a nationwide 368 cross-sectional study among civilians and military 369 professionals. PLOS ONE. 2014;9:e87669. 370

32. Hassing RJ, van der Eijk AA, Lopes VB, et al. Hepatitis E 371 prevalence among HIV infected patients with elevated liver 372 enzymes in the Netherlands. J Clin Virol. 2014;60:408-10. 373